Healthcare

Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD Landscape

Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…

ByByAnuja Singh Mar 5, 2026

Has China Now Overtaken the US at the Heart of Biotech Innovation?

Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the…

ByByAnuja Singh Mar 4, 2026

Is Hong Kong Becoming Asia’s AI–Biopharma Hub?

Hong Kong is emerging as a key AI‑biopharma hub, with recent deals like Earendil Labs’ partnership with Sanofi…

ByByAnuja Singh Mar 4, 2026

Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?

Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…

ByByAnuja Singh Mar 4, 2026
Image Not Found

Can Sanofi SA’s New AI-Enabled Innovation Hub in China Accelerate Global Drug Development and Reshape Biopharma Operations Across Asia?

Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…

ByByAnuja Singh Mar 24, 2026

Can Sanofi SA’s $1.2 Billion AI-Driven Autoimmune Alliance with Kali Therapeutics Inc Unlock Next-Gen Tri-Specific Antibody Therapies and Disrupt Immunology Markets?

Key Highlights: AI-Powered Biologics Platforms Accelerate Next-Gen Antibody DiscoverySanofi SA’s licensing agreement with Kali Therapeutics Inc highlights the…

ByByAnuja Singh Mar 24, 2026
Scroll to Top